We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
Read MoreHide Full Article
Key Takeaways
AstraZeneca's Sone-Ve BLA wins FDA priority review for certain advanced gastric and GEJ cancers.
The FDA's decision is expected in Q2 2027, accelerating the regulatory review timeline.
AZN's BLA filing for Sone-Ve was based on positive data from the phase III CLARITY-Gastric01 study.
AstraZeneca (AZN - Free Report) announced that the FDA has accepted its biologics license application (BLA) seeking approval for an investigational Claudin 18.2-targeting antibody-drug conjugate (ADC), sonesitatug vedotin (Sone-Ve), in patients with certain types of gastric cancers.
The drug has been developed for the treatment of patients with advanced or metastatic gastric cancer, GEJ cancer and oesophageal adenocarcinoma who have received at least one prior line of treatment and whose tumors express CLDN18.2 protein in at least 25% of cells.
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected in the second quarter of 2027.
A priority review designation means the FDA’s goal is to take action on an application within six months compared with 10 months under standard review.
Sone-Ve is under regulatory review in the European Union, China and several other countries for gastric/GEJ cancers.
Sone-Ve was added to AstraZeneca’s pipeline following a global exclusive licensing agreement with KYM Biosciences in March 2023 for its development and commercialization.
Year to date, shares of AstraZeneca have lost 3.6% against the industry’s 5.6% growth.
Image Source: Zacks Investment Research
AZN’s Strong Phase III Data Support Sone-Ve’s BLA Filing
The BLA filing for Sone-Ve was supported by positive data from the phase III CLARITY-Gastric01 study, in which the candidate reduced the risk of death by 42% compared with standard treatment. Patients receiving Sone-Ve achieved a median overall survival of 10.6 months versus 6.4 months for those receiving other therapies. The survival benefit was generally consistent across predefined patient subgroups, including those with different levels of CLDN18.2 expression.
Sone-Ve Expands AstraZeneca’s Oncology Pipeline
Sone-Ve is an investigational ADC designed to target CLDN18.2, a protein commonly expressed in gastric and GEJ cancers. AstraZeneca is evaluating the candidate in combination with other therapies in earlier-line gastric cancer settings and in additional gastrointestinal cancers, including pancreatic and biliary tract cancers. The company has entered into a clinical collaboration with Summit Therapeutics (SMMT - Free Report) to evaluate Sone-Ve in combination with the latter’s ivonescimab in gastrointestinal cancers. Under the agreement, AstraZeneca and Summit Therapeutics will contribute their respective medicines and jointly share the costs of clinical development.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 32.2% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 72.7% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.
Image: Bigstock
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
Key Takeaways
AstraZeneca (AZN - Free Report) announced that the FDA has accepted its biologics license application (BLA) seeking approval for an investigational Claudin 18.2-targeting antibody-drug conjugate (ADC), sonesitatug vedotin (Sone-Ve), in patients with certain types of gastric cancers.
The drug has been developed for the treatment of patients with advanced or metastatic gastric cancer, GEJ cancer and oesophageal adenocarcinoma who have received at least one prior line of treatment and whose tumors express CLDN18.2 protein in at least 25% of cells.
With the FDA granting a priority review to the BLA, a decision from the regulatory body is expected in the second quarter of 2027.
A priority review designation means the FDA’s goal is to take action on an application within six months compared with 10 months under standard review.
Sone-Ve is under regulatory review in the European Union, China and several other countries for gastric/GEJ cancers.
Sone-Ve was added to AstraZeneca’s pipeline following a global exclusive licensing agreement with KYM Biosciences in March 2023 for its development and commercialization.
Year to date, shares of AstraZeneca have lost 3.6% against the industry’s 5.6% growth.
Image Source: Zacks Investment Research
AZN’s Strong Phase III Data Support Sone-Ve’s BLA Filing
The BLA filing for Sone-Ve was supported by positive data from the phase III CLARITY-Gastric01 study, in which the candidate reduced the risk of death by 42% compared with standard treatment. Patients receiving Sone-Ve achieved a median overall survival of 10.6 months versus 6.4 months for those receiving other therapies. The survival benefit was generally consistent across predefined patient subgroups, including those with different levels of CLDN18.2 expression.
Sone-Ve Expands AstraZeneca’s Oncology Pipeline
Sone-Ve is an investigational ADC designed to target CLDN18.2, a protein commonly expressed in gastric and GEJ cancers. AstraZeneca is evaluating the candidate in combination with other therapies in earlier-line gastric cancer settings and in additional gastrointestinal cancers, including pancreatic and biliary tract cancers. The company has entered into a clinical collaboration with Summit Therapeutics (SMMT - Free Report) to evaluate Sone-Ve in combination with the latter’s ivonescimab in gastrointestinal cancers. Under the agreement, AstraZeneca and Summit Therapeutics will contribute their respective medicines and jointly share the costs of clinical development.
AZN’s Zacks Rank & Stocks to Consider
AZN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 32.2% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.
Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 72.7% year to date.
Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.